Cancer drug development halted following trial deaths
Mirna Therapeutics Inc. (Austin, TX, USA) halts drug development of its flag-ship oncology drug MRX34 following adverse trial results, culminating with the deaths of clincal trial participants.
Please sign in or register for FREE
Sign in to MedChemNet
Register to MedChemNet – the medicinal chemistry network
MedChemNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.